RecruitingPhase 2NCT06862960
Ozanimod in Patients With Alzheimer's Disease
Ozanimod for the Treatment of Alzheimer's Disease: a Proof-of-concept Study
Sponsor
ChenXiaoChun
Enrollment
40 participants
Start Date
Aug 13, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to investigate the benefits of ozanimod in patients with moderate Alzheimer's disease.
Eligibility
Min Age: 55 YearsMax Age: 80 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Conventional medication and a drug called Ozanimod for people with alzheimer disease. The study is currently recruiting participants at 1 location. People eligible for this study include aged 55 Years to 80 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGOzanimod
A sphingosine-1-phosphate receptor regulator
DRUGConventional medication
Conventional medications for moderate AD
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06862960
Related Trials
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
NCT0684732140 locations
An Observational Study on Lecanemab Treatment for Early Alzheimer's Disease
NCT071538482 locations
Cannabidiol Medication Intervention Trial
NCT060144245 locations
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787292 locations
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229258 locations